A new state-of-the-art lab has opened in the UK to accelerate the development of cancer diagnostic solutions. Vortex Biotech has opened a new laboratory at Manchester Science Park, hoping to accelerate the development of cancer diagnostic solutions. The laboratories are designed to GLP-ready specifications, allowing future expansion into clinical trial support and commercial product… Read More
Richard Staines reviews the emergence of autotaxin (ATX) inhibition as a transformative approach in oncology, with the potential to expand into other diseases, including liver malignancies. Autotaxin (ATX) inhibition is emerging as a promising therapeutic strategy in oncology, with potential relevance to chronic liver disease and beyond. Although early trials in idiopathic pulmonary fibrosis (IPF)… Read More
DDW Editor Reece Armstrong speaks to Aron Knickerbocker, CEO of Aulos Bioscience, about the company’s efforts in the immuno-oncology field and how it is hoping to revitalise a therapeutic area that initially held promise many years ago. The number of available treatment options for cancer patients has risen drastically… Read More
The ATR inhibitor alnodesertib has been granted fast track designation by the US Food and Drug Administration (FDA), biopharmaceutical company Artios Pharma Limited has announced. Alnodesertib is a treatment for adult patients with ATM negative metastatic colorectal cancer (mCRC) in the third-line setting, in combination with a… Read More
Download this whitepaper by Standard BioTools to learn about the tumour microenvironment (TME) and the protein biomarkers helping to shape cancer outcomes. The tumour microenvironment (TME) is no longer considered a passive backdrop to cancer. It is a dynamic ecosystem that plays a central role in tumour growth, immune suppression,… Read More
A new study has revealed that the mechanical environment surrounding a tumour can cause cancer cells to change their behaviour, triggering a switch from rapid growth to a more invasive, drug-resistant state. Traditionally, epigenetic changes have been thought to arise from internal cellular processes, such as histone… Read More
Biotechnology company Insilico Medicine has unveiled a new study showcasing how the company’s advanced generative AI platform and integrated workflow helped to identify and validate ENPP1 as a critical immune checkpoint among multiple solid tumours, which helped to the development of a highly specific oral ENPP1 inhibitor, ISM5939. Read More
The American Association of Cancer Research (AACR) Annual Meeting took place from 25-30 April at the McCormick Place Convention Center in Chicago, US. DDW’s Megan Thomas looks at key announcements, presentations and breakthroughs that took place. Presidential commentary On Sunday 27 April, attendees were welcomed at the Opening Ceremony by… Read More
This is the latest episode of the free DDW narrated podcast, titled “Where is the innovation in the therapeutic antibody market?”, which covers two articles written for DDW Volume 24 – Issue 3, Summer 2023. They are called: “Finding the North Star of therapeutic antibodies” and “Which diseases… Read More
DDW’s Megan Thomas spoke with industry experts about their predictions for drug discovery opportunities in 2025. Previously, with a focus on technology, machine learning (ML) and artificial intelligence (AI), as well as neuroscience. Here, looking at cancer burden and research in the sector. Ahead of World Cancer Day… Read More
Redx Pharma has announced data from all Phase II clinical trial modules of zamaporvint (RXC004), a potent, selective, orally-active Porcupine inhibitor in development for Wnt-ligand dependent, hard-to-treat gastrointestinal (GI) cancers. These data, presented at the European Society for Medical Oncology Gastrointestinal Cancers (ESMO GI) Congress, were from… Read More
DDW Editor Reece Armstrong speaks to Jasminka Taleska, Director, RLT HCS Readiness and Policy at Novartis, about the opportunities radioligand therapies (RLTs) represent in treating cancer patients. RA: What are the potentials of RLTs across cancer? JT: Cancer is an incredibly complex and… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. A leading news story this week has been the announcement of positive Phase II… Read More
News round-up for 6-10 May by DDW Multimedia Editor Megan Thomas. A leading news story this week has been the announcement of positive Phase II results of a head and neck cancer trial, but there have been a number of other interesting clinical result announcements. These include the… Read More
Immune B cells could be used to develop cancer targeting immunotherapies, following new research by scientists at The Institute of Cancer Research, London, the University of Oxford and University of Cambridge. The scientists discovered the role of immune B cells which makes them successful at targeting tumours,… Read More
A clinical trial of a personalised mRNA cancer vaccine for melanoma patients has been launched in the UK. As reported by The Guardian, the global Phase III clinical trial is being led by University College London Hospitals NHS Foundation Trust (UCLH) and… Read More
